EPISODE · Mar 30, 2024 · 7 MIN
Tumore endometriale avanzato
from Salute e Società · host Marco Caracciolo
Dostarlimab più chemioterapia è l'unica combinazione immuno-oncologica a mostrare una riduzione del 30% rischio di morte in tutta la popolazione di pazienti con carcinoma endometriale primario avanzato o ricorrente. Lo indicano i dati dello studio Ruby, diffusi da Gsk e presentati a San Diego al Meeting annuale sui tumori ginecologici.
Embed this episode
NOW PLAYING
Tumore endometriale avanzato
0:00
7:02
1×
No transcript for this episode yet
Similar Episodes
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Salute e Società?
This episode is 7 minutes long.
When was this Salute e Società episode published?
This episode was published on March 30, 2024.
Can I download this Salute e Società episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!